Business
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of ...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nOncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer\nCanada NewsWire\nEDMONTON, Nov. 2, 2016\n\n\n\nSigned Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies\n\n\n\nEDMONTON, Nov. 2, 2016 /CNW/ - OncoQuest Inc. (\"OncoQuest'), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced that its Joint Venture Partner in China, OncoVent Co., Ltd. (\"OncoVent\") has launched its clinical development program for Anti-MUC1 MAb AR20.5 for the treatment of pancreatic cancer. Based on previous clinical experience and recently announced positive pre-clinical data on combinatory immunotherapy in the pancreatic cancer model, OncoVent has started implementing its clinical development plan, and has signed an agreement with a U.S. based cGMP cell culture bioproduction facility, Cell Culture Company (C3), located in Minneapolis US, to manufacture clinical grade MAb AR20.5. The manufactured antibody is intended to be used to support a planned U.S. clinical trial for the treatment of pancreatic cancer, followed by additional studies worldwide, including China. \n\nOncoVent is a China-based joint venture company formed by Shenzhen Hepalink Pharmaceutical Co., Ltd. (\"Shenzhen Hepalink\") and OncoQuest. OncoVent licensed its Antibody based Immunotherapy Technology from OncoQuest for the Greater China territory, and is supported by a US $5 million investment by Shenzhen Hepalink as well as a US $1 million investment by OncoQuest. Dr. Yuenian Shi (Dr. Eric Shi), co-founder of OncoVent has been appointed as its Director and Chief Executive Officer. A biomedical scientist specializing in cancer research and translational medicine development, Dr. Shi was Professor at the Albert Einstein College of Medicine prior to hi...